Basic Information
VIS ID
TVIS30014069
Fusion event
HIV-RTTN integration
Validated
Yes
Detection method
invPCR
Data source
download(RID)
Sample type
PBMC
Disease
HIV-infected disease (HID)
Quality evaluation
Normal
Reported year
2007
PubMed ID
17262715
Virus Sequence
Virus name
HIV
Reference genome
Not given
Host Sequence
Chromosome
chr18
Cytoband
q22.2
Reference genome
GRCh37/hg19
Start
67837922/70170686 (Hg38)
End
67837922/70170686 (Hg38)
Orient
-
Location type
Intronic
Target gene
RTTN
miRNAs that regulate target gene
hsa-mir-17-5p ; hsa-mir-628-5p ; hsa-mir-6739-5p ; hsa-mir-6733-5p ; hsa-mir-3153 ; hsa-mir-4668-5p ; hsa-mir-4766-5p ; hsa-mir-8062 ; hsa-mir-1278 ; hsa-mir-495-5p ; hsa-mir-548ah-5p ; hsa-mir-3609 ; hsa-mir-6836-3p ; hsa-mir-6829-3p ; hsa-mir-6791-3p ; hsa-mir-6778-3p ; hsa-mir-4695-3p ; hsa-mir-4772-3p ; hsa-mir-7113-3p ; hsa-mir-6787-3p ; hsa-mir-1304-3p ; hsa-mir-6747-3p ; hsa-mir-6752-3p ; hsa-mir-6736-3p ; hsa-mir-6890-3p ; hsa-mir-7641 ; hsa-mir-3622b-5p ; hsa-mir-4726-3p ; hsa-mir-6764-5p ; hsa-mir-1915-3p ; hsa-mir-6840-3p ; hsa-mir-8055 ; hsa-mir-129-5p ; hsa-mir-6864-3p ; hsa-mir-3672 ; hsa-mir-431-5p ; hsa-mir-6879-3p ; hsa-mir-1251-3p ; hsa-mir-924 ; hsa-mir-4524a-3p ; hsa-mir-500b-3p ; hsa-mir-5007-5p ; hsa-mir-4797-5p ; hsa-mir-153-5p ; hsa-mir-1976 ; hsa-mir-20a-3p ; hsa-mir-4326 ; hsa-mir-4691-5p ; hsa-mir-5193 ; hsa-mir-660-3p ; hsa-mir-6749-3p ; hsa-mir-6792-3p
Nearest miRNA
hsa-mir-1-2/Upstream/3089000; hsa-mir-548av/Downstream/2682635;
Nearest TSS
ENST00000575820/Upstream/20668; ENST00000578377/Downstream/27000;
Nearest CpG islands
None/Target, chr18-CpG: 67/Upstream/700674, chr18-CpG: 80/Downstream/34599
Upstream sequence
gaaagccagtggagctggttctgagggatggagtcagaaaggagtggtgggccagatcagttaaggctttgggtcgtcataaggaattgtcctctgctga
Downstream sequence
aagccactggaacattttaaacaagtatcaaaattggtctgtagagaactgatggtaatgtgcaaaagtggaagctaagagacagaggactttactgcag
Reference
Ikeda, T., et al. Recurrent HIV-1 integration at the BACH2 locus in resting CD4+ T cell populations during effective highly active antiretroviral therapy. J Infect Dis,2007, 195(5): 716-725.
Curate